AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02637778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardioprotective diet
Description: The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
Study NCT02637778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardioprotective diet + 3 g EPA + DHA/d
Description: The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
Study NCT00035464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide Dihydrochloride
Description: 125 mg azimilide tablets, twice a day for 6 months
Study NCT00035464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets, twice a day for 6 months
Study NCT02794662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen Environment
Description: FiO2 delivered by servo-controlled incubator
Study NCT02794662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula Oxygen
Description: FiO2 delivered by nasal cannula
Study NCT02089529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no information, positive information and neutral information
Study NCT04152109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laying on of hands by Spiritual Passe
Description: The participants will be subjected application of the laying on of hands by the volunteer who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks.
Study NCT03860181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular Sutures - Surgeon 1
Description: This intervention closes incisions after shoulder arthroplasty using subcuticular sutures with Dermabond.The deep layer closure will require interrupted sutures.
Study NCT03860181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal Staples - Surgeon 2
Description: This intervention closes incisions after shoulder arthroplasty with metal staples. The deep layer closure will require interrupted sutures,
Study NCT03860181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRINEO - Surgeon 1
Description: The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
Study NCT03860181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRINEO - Surgeon 2
Description: The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
Study NCT01931189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NI-071
Description: 100mg/vial
Study NCT01931189 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 100mg/vial
Study NCT00072215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: given IV
Study NCT00072215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: given IV
Study NCT00072215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: given IV
Study NCT00072215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: given IV
Study NCT02561273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous stem cell transplant
Study NCT02561273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02561273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02561273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02561273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02561273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02561273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplant
Study NCT02561273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02561273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT04864184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal physiologic rate breathing
Description: 2-minute breathing exercises will be completed every 15 minutes.
Study NCT04864184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow breathing
Description: 2-minute breathing exercises will be completed every 15 minutes.
Study NCT00779961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatoplasty
Description: Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
Study NCT00779961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatoplasty
Description: Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
Study NCT03323606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gambling Internet Intervention
Description: The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
Study NCT03323606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Internet Intervention
Description: The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
Study NCT03323606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking
Description: A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
Study NCT04246814 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG1
Description: Application of LASER AsGa 904nm 10 J/cm².
Study NCT04246814 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG2
Description: Application of LASER AsGa 904nm 8 J/cm².
Study NCT04246814 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG3
Description: Application of LASER AsGa 904nm 4 J/cm².
Study NCT04246814 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CC
Description: Application of placebo LASER.
Study NCT04246814 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.
Study NCT04246814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.
Study NCT01109771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: permanent mesh fixation
Description: Permanent mesh fixation will be used.
Study NCT01109771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: absorbable mesh fixation
Description: Absorbable mesh fixation will be used.
Study NCT02845076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol for weaning of noninvasive ventilation
Description: 3 protocols for weaning of noninvasive ventilation will be compared
Study NCT01612455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINC Case Management
Description: The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
Study NCT00987493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: day 1 at a fixed dose of 375mg/m2
Study NCT00987493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
Study NCT00987493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
Study NCT04109833 — intervention group
Intervention type: DRUG
Intervention: ABT
Description: any antibiotic therapy in the first week of life
Study NCT03947970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] CR845
Description: Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
Study NCT01913704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NatroxTM Device
Description: The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks.
Study NCT01913704 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NatroxTM Device
Description: The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks.
Study NCT03331783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard hydrocolloid adhesive patch
Description: This patch is made of a standard hydrocolloid adhesive
Study NCT03331783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LT-2
Description: This patch is made of a new adhesive
Study NCT03331783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LT-21
Description: This patch is made of a new adhesive
Study NCT03331783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 33-20
Description: This patch is made of a new adhesive
Study NCT00853840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
Study NCT03016962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cap-assisted colonoscopy
Description: cap-assisted colonoscopy
Study NCT03016962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy
Description: Standard colonoscopy
Study NCT00441311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
Study NCT00853840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
Study NCT02913391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: recruitment group (RG)
Description: After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
Study NCT02913391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group (CG)
Description: After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
Study NCT00853840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
Study NCT02308254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide
Description: Abdominal administration
Study NCT02308254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Abdominal administration
Study NCT01161914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerezyme®
Description: administered by IV infusion for a dose of 60 U/kg
Study NCT01161914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISU302
Description: administered by IV infusion for a dose of 60 U/kg
Study NCT00497172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER Sirolimus-eluting stent
Description: drug-eluting stent
Study NCT00853840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
Study NCT04287686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human angiotensin-converting enzyme 2 (rhACE2)
Description: In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.
Study NCT05647668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic fundoplication
Description: Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.
Study NCT00497172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bx SONIC bare metal stent
Description: bare-metal stent
Study NCT04150276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ZEEP during awakening
Description: ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
Study NCT02184429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
Study NCT02184429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
Study NCT02184429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
Study NCT02184429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
Study NCT02184429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
Study NCT02184429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
Study NCT02184429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
Study NCT03344198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit Training exercise & Modified Mediterranean diet
Description: Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.
Study NCT02008357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT02008357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solanezumab
Description: Administered IV
Study NCT02008357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Administered IV
Study NCT04239300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delivery in water
Description: Participants delivery in water
Study NCT03715192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3462817 IV
Description: Administered IV
Study NCT03715192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3462817 SC
Description: Administered SC
Study NCT03715192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT03235219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study NCT03235219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study NCT03262116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog
Description: Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
Study NCT04150276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP during awakening
Description: PEEP will be maintained throughout emergence preoxygenation and awakening.
Study NCT03262116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog
Description: Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
Study NCT03262116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC222 insulin lispro
Description: Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
Study NCT03262116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: The insulin-only bionic pancreas will be used in all three arms of the study
Study NCT00117793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Surface Bearing Suction Socket
Description: Current clinical practice
Study NCT00117793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum assisted socket system
Description: Novel socket system